C-reactive protein in critically ill cancer patients with sepsis: Influence of neutropenia

Critical Care

Volumn 15, Issue 3, 2011, Pages

  Póvoa, Pedro ^a,b   Souza Dantas, Vicente C ^c   Soares, Márcio ^c,d   Salluh, Jorge I F ^c,d  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^d D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; BLOOD; CRITICAL ILLNESS; MIDDLE AGED; NEOPLASM; SEPSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SEPSIS; TREATMENT OUTCOME;

EID: 79955984559     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10242     Document Type: Article

References (37)

1. Soares M, Caruso P, Silva E, Teles JM, Lobo SM, Friedman G, Dal Pizzol F, Mello PV, Bozza FA, Silva UV, Torelly AP, Knibel MF, Rezende E, Netto JJ, Piras C, Castro A, Ferreira BS, Rea-Neto A, Olmedo PB, Salluh JI. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med 2010, 38:9-15. 10.1097/CCM.0b013e3181c0349e, 19829101.
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751. 10.1086/339215, 11850858.
3. Sharma A, Lokeshwar N. Febrile neutropenia in haematological malignancies. J Postgrad Med 2005, 51:S42-48.
4. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, et al. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990, 161:381-396. 10.1093/infdis/161.3.381, 2179420.
5. Gaeta GB, Fusco FM, Nardiello S. Fever of unknown origin: a systematic review of the literature for 1995-2004. Nucl Med Commun 2006, 27:205-211. 10.1097/00006231-200603000-00002, 16479239.
6. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care 2006, 10:R63. 10.1186/cc4892, 1550913, 16635270.
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454. 10.1056/NEJM199902113400607, 9971870.
8. Sudhoff T, Giagounidis A, Karthaus M. Serum and plasma parameters in clinical evaluation of neutropenic fever. Antibiot Chemother 2000, 50:10-19.
9. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008, 36:396-407. 10.1007/s15010-008-7374-y, 18759057.
10. Souza-Dantas VC, Salluh JI, Soares M. Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case-control study. Ann Oncol 2011,
11. Soares M, Salluh JI, Torres VB, Leal JV, Spector N. Short- and long-term outcomes of critically ill patients with cancer and prolonged ICU length of stay. Chest 2008, 134:520-526. 10.1378/chest.08-0359, 18641110.
12. Soares M, Silva UV, Teles JM, Silva E, Caruso P, Lobo SM, Dal Pizzol F, Azevedo LP, de Carvalho FB, Salluh JI. Validation of four prognostic scores in patients with cancer admitted to Brazilian intensive care units: results from a prospective multicenter study. Intensive Care Med 2010, 36:1188-1195. 10.1007/s00134-010-1807-7, 20221751.
13. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353. 10.1097/01.CCM.0000194725.48928.3A, 16424713.
14. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care 2009, 13:R15. 10.1186/cc7713, 2688132, 19200368.
15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256. 10.1097/01.CCM.0000050454.01978.3B, 12682500.
16. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.270.24.2957, 8254858.
17. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
18. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, Schmidt-Wolf IG, Marklein G, Schroeder S, Stuber F. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004, 23:539-544.
19. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krcmery V, Menichetti F, Panaretou E, Papageorgiou E, Plachouras D. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 2004, 10:628-633. 10.1111/j.1469-0691.2004.00883.x, 15214875.
20. Erten N, Genc S, Besisik SK, Saka B, Karan MA, Tascioglu C. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc 2004, 67:217-221.
21. Massaro KS, Costa SF, Leone C, Chamone DA. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 2007, 7:137. 10.1186/1471-2334-7-137, 2217552, 18034890.
22. Prat C, Sancho JM, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008, 49:1752-1761. 10.1080/10428190802258956, 18661397.
23. Hamalainen S, Juutilainen A, Matinlauri I, Kuittinen T, Ruokonen E, Koivula I, Jantunen E. Serum vascular endothelial growth factor in adult haematological patients with neutropenic fever: a comparison with C-reactive protein. Eur J Haematol 2009, 83:251-257. 10.1111/j.1600-0609.2009.01260.x, 19302556.
24. Buyukberber N, Buyukberber S, Sevinc A, Camci C. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol 2009, 26:55-61. 10.1007/s12032-008-9081-z, 18686048.
25. Ortega M, Rovira M, Almela M, de la Bellacasa JP, Carreras E, Mensa J. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 2004, 33:741-744. 10.1038/sj.bmt.1704409, 14730343.
26. Hamalainen S, Juutilainen A, Kuittinen T, Nousiainen T, Matinlauri I, Pulkki K, Koivula I, Jantunen E. Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein. Leuk Lymphoma 2010, 51:1040-1046. 10.3109/10428191003743478, 20470220.
27. Moon JM, Chun BJ. Predicting the complicated neutropenic fever in the emergency department. Emerg Med J 2009, 26:802-806. 10.1136/emj.2008.064865, 2773519, 19850806.
28. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 2006, 43:468-473. 10.1086/505394, 16838236.
29. Monton C, Ewig S, Torres A, El-Ebiary M, Filella X, Rano A, Xaubet A. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999, 14:218-220. 10.1034/j.1399-3003.1999.14a37.x, 10489855.
30. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248.
31. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, Narumoto O, Kichikawa Y, Kawai M, Tashimo H, Arai H, Horiuchi T, Sakamoto Y. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007, 185:249-255. 10.1007/s00408-007-9020-3, 17710485.
32. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008, 32:726-732. 10.1183/09031936.00003608, 18508833.
33. Salluh JI, Soares M, Coelho LM, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, Silva JR, Bozza PT, Povoa P. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: A cohort study. J Crit Care 2011, 26:193-200. 10.1016/j.jcrc.2010.07.014, 20889284.
34. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003, 123:2043-2049. 10.1378/chest.123.6.2043, 12796187.
35. Lisboa T, Seligman R, Diaz E, Rodriguez A, Teixeira PJ, Rello J. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:166-171. 10.1097/01.CCM.0000297886.32564.CF, 18007271.
36. Rello J, Lisboa T, Lujan M, Gallego M, Kee C, Kay I, Lopez D, Waterer GW. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009, 136:832-840. 10.1378/chest.09-0258, 19433527.
37. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010, 14:203. 10.1186/cc8155, 2875480, 20236471.